Numerical Modeling Articles & Analysis: Older
1 news found
Lung Therapeutics, Inc., a clinical stage pharmaceutical company developing novel therapeutics for niche, orphan drug indications in fibrosis, lung injury and disease, announced today the successful completion of a $14.3 million Series B financing. The proceeds will support ongoing LTI-01 clinical trials in Australia and New Zealand, as well as development activities to advance the Company's ...